Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops (AKORN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02758327
Recruitment Status : Completed
First Posted : May 2, 2016
Last Update Posted : August 18, 2017
Sponsor:
Collaborator:
Akorn, Inc.
Information provided by (Responsible Party):
Koffler Vision Group

Brief Summary:
The objective of the study is to demonstrate a change in osmolarity over time when moderate to severe dry eye subjects are treated with TheraTears lubricating drops.

Condition or disease Intervention/treatment Phase
Dry Eye Syndrome Drug: TheraTears Lubricating Eye Drops Phase 4

Detailed Description:
Symptomatic dry eye subjects exhibited a significantly higher tear osmolarity than observed in normal subjects, this is thought to relate to the inherent tear film instability of dry eye disease. Lubricating eye drops are frequently prescribed to relieve the symptoms of dry eye.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating
Study Start Date : October 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tears

Arm Intervention/treatment
Experimental: TheraTears Lubrication Drop
TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks.
Drug: TheraTears Lubricating Eye Drops
Sodium Carboxy-methylcellulose 0.25% eye Lubricant
Other Name: 87049747




Primary Outcome Measures :
  1. Change in Tear Osmolarity [ Time Frame: 8 weeks ]
    Osmolarity measures will be evaluated using the eye with the highest osmolarity reading at the washout/baseline visit. These baseline values will be compared to subsequent follow-up visits, to determine change from baseline at each visit as well as cumulative change in osmolarity over time.


Secondary Outcome Measures :
  1. Change in Visual Acuity [ Time Frame: 8 weeks ]
    Visual acuity measures will be evaluated using the eye with the highest osmolarity reading at the washout/baseline visit. These baseline values will be compared to subsequent follow-up visits, to determine change from baseline at each visit as well as cumulative change in visual acuity over time.

  2. Change in Tear Film Breakup Time [ Time Frame: 8 Weeks ]
    After instillation of fluorescein, the investigator will ask the participant blink three times and keep their eyes open for as long as they can while the investigator records the time at which the dark spots on the tear film begin to appear.

  3. Change in Corneal Staining [ Time Frame: 8 weeks ]
    A fluorescein strip will be wetted with a few drops of saline, and applied to the inferior palpebral conjunctiva of both eyes. The eye will be illuminated by cobalt blue light, and viewed through a Wratten no. 12 barrier filter. Fluorescein staining will be assessed using the CCLRU8 scale (0 to 4).

  4. Change in Conjunctiva Staining [ Time Frame: 8 Weeks ]
    A lissamine green strip will be wetted and applied to the inferior palpebral conjunctiva of both eyes to assess conjunctival staining. Lissamine conjunctival staining will be assessed using the Oxford scale. If lissamine strip is not available, fluorescein maybe used instead to assess all conjunctival staining.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Is at least 21 years of age and has full legal capacity to volunteer;
  2. Has read and signed the information consent letter;
  3. Is willing and able to follow instructions and maintain the appointment schedule;
  4. Is diagnosed with dry eye syndrome (in at least one eye), indicated by current ocular examination, prior history (self-reported history of dry eye is acceptable) and current use of treatments for dry eye;
  5. Has a minimum osmolarity reading of 316 mosm/kg at the baseline visit in at least one eye or a osmolarity reading of at least 308 (in worse eye) and at least an 8 point difference between the two eyes.

Exclusion Criteria:

  1. Has taken part in another research study within the last 30 days;
  2. Planned contact lens wear during the course of the study;
  3. Staff at the investigational site or family member of site staff or family member of currently enrolled participant;
  4. Any subject that violates the washout period by using eye drops during the 72hrs washout period;
  5. Has any known ocular disease* including active ocular infection, inflammation or allergy, especially Salzmann's nodular degeneration, symptomatic conjunctivochalasis, and fixation disparity syndrome;
  6. Restasis use can be included if they have been on it for at least 3 months and are stable.Used Restasis (or similar topical medication) within the last 6 months;
  7. Has a systemic condition that in the opinion of the investigator may affect the dry eye status of the subject, especially those newly diagnosed, newly prescribed and/or unstable;
  8. Is pregnant, lactating or planning a pregnancy at the time of enrolment (verbal confirmation necessary);
  9. Use of systemic anti-histamines, as long as they have been on them continuously for at least 1 month. Use of medications such as: Systemic Antihistamine (e.g., Allegra®, Benadryl®, Claritin®, Dimetapp®, Unisom®, Zyrtec®, etc.), Isotretinoin (e.g., Accutane®, Roaccutane®, Amnesteem®, Claravis®, Isotroin®, Sotret®) or similar medications;
  10. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
  11. Has undergone ocular surgery(LASIK, Cataract, etc)within the last year;

    • For purposes of this study, ocular conditions that are typically associated with dry eye status, such as meibomian gland dysfunction, mild (i.e. not considered clinically relevant) blepharitis, corneal and conjunctival staining are not considered an exclusion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02758327


Sponsors and Collaborators
Koffler Vision Group
Akorn, Inc.
Investigators
Layout table for investigator information
Study Director: Diane Houtman, MD Akorn Pharmaceuticals
Layout table for additonal information
Responsible Party: Koffler Vision Group
ClinicalTrials.gov Identifier: NCT02758327    
Other Study ID Numbers: ACH_PM_101_14
First Posted: May 2, 2016    Key Record Dates
Last Update Posted: August 18, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Koffler Vision Group:
Tear Osmolarity
Keratitis Sicca
Ocular Surface Disease
TheraTears
Additional relevant MeSH terms:
Layout table for MeSH terms
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Carboxymethylcellulose Sodium
Ophthalmic Solutions
Lubricant Eye Drops
Pharmaceutical Solutions
Laxatives
Gastrointestinal Agents